Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Total Current Liabilities of $148.7 million for Q1 2026, up 32.89% year-over-year from $111.9 million in Q1 2025, and up 12.48% quarter-over-quarter from $132.2 million in Q4 2025.
Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $148.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 32.89% year-over-year to $148.7 million; the TTM figure through Mar 2026 stood at $148.7 million (up 32.89% YoY), while the FY2025 annual figure was $132.2 million, down 18.6% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $148.7 million, up from $132.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.2 billion in Q4 2022, with the low at $111.9 million in Q1 2025.
- The 5-year median for Total Current Liabilities is $264.4 million (2022), against an average of $443.6 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 387.84% in 2023, then plunged 82.24% in 2025.
- Emergent BioSolutions' Total Current Liabilities stood at $1.2 billion in 2022, then plunged by 47.0% to $651.3 million in 2023, then sank by 75.07% to $162.4 million in 2024, then declined by 18.6% to $132.2 million in 2025, then climbed by 12.48% to $148.7 million in 2026.
- Business Quant data shows EBS's Total Current Liabilities at $148.7 million in Q1 2026, $132.2 million in Q4 2025, and $136.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 122.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.80 Mn |
| Mar 31, 2026 | 148.70 Mn |
| Dec 31, 2025 | 132.20 Mn |
| Sep 30, 2025 | 136.50 Mn |
| Jun 30, 2025 | 127.10 Mn |
| Mar 31, 2025 | 111.90 Mn |
| Dec 31, 2024 | 162.40 Mn |
| Sep 30, 2024 | 229.90 Mn |
| Jun 30, 2024 | 619.70 Mn |
| Mar 31, 2024 | 630.20 Mn |
| Dec 31, 2023 | 651.30 Mn |
| Sep 30, 2023 | 664.00 Mn |
| Jun 30, 2023 | 693.20 Mn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Sep 30, 2022 | 264.40 Mn |
| Jun 30, 2022 | 276.70 Mn |
| Mar 31, 2022 | 249.20 Mn |
| Dec 31, 2021 | 374.00 Mn |
| Sep 30, 2021 | 365.40 Mn |